This company has been marked as potentially delisted and may not be actively trading. GX Acquisition (GXGX) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock GXGX vs. XOMA, ABEO, PHAT, TRDA, IMMP, HRTX, NGNE, TERN, NATR, and GOSSShould you be buying GX Acquisition stock or one of its competitors? The main competitors of GX Acquisition include XOMA (XOMA), Abeona Therapeutics (ABEO), Phathom Pharmaceuticals (PHAT), Entrada Therapeutics (TRDA), Immutep (IMMP), Heron Therapeutics (HRTX), Neurogene (NGNE), Terns Pharmaceuticals (TERN), Nature's Sunshine Products (NATR), and Gossamer Bio (GOSS). These companies are all part of the "medical" sector. GX Acquisition vs. XOMA Abeona Therapeutics Phathom Pharmaceuticals Entrada Therapeutics Immutep Heron Therapeutics Neurogene Terns Pharmaceuticals Nature's Sunshine Products Gossamer Bio XOMA (NASDAQ:XOMA) and GX Acquisition (NASDAQ:GXGX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, valuation, risk, earnings, profitability, institutional ownership, analyst recommendations and community ranking. Is XOMA or GXGX more profitable? GX Acquisition has a net margin of 0.00% compared to XOMA's net margin of -151.34%. XOMA's return on equity of -24.95% beat GX Acquisition's return on equity.Company Net Margins Return on Equity Return on Assets XOMA-151.34% -24.95% -9.64% GX Acquisition N/A -985.20%-6.02% Do institutionals & insiders hold more shares of XOMA or GXGX? 95.9% of XOMA shares are held by institutional investors. Comparatively, 61.7% of GX Acquisition shares are held by institutional investors. 7.2% of XOMA shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the media prefer XOMA or GXGX? In the previous week, XOMA had 13 more articles in the media than GX Acquisition. MarketBeat recorded 13 mentions for XOMA and 0 mentions for GX Acquisition. XOMA's average media sentiment score of 0.69 beat GX Acquisition's score of 0.00 indicating that XOMA is being referred to more favorably in the media. Company Overall Sentiment XOMA Positive GX Acquisition Neutral Which has better valuation & earnings, XOMA or GXGX? XOMA has higher revenue and earnings than GX Acquisition. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioXOMA$13.05M22.78-$40.83M-$1.15-21.60GX AcquisitionN/AN/A-$49.26MN/AN/A Does the MarketBeat Community favor XOMA or GXGX? XOMA received 440 more outperform votes than GX Acquisition when rated by MarketBeat users. However, 100.00% of users gave GX Acquisition an outperform vote while only 65.58% of users gave XOMA an outperform vote. CompanyUnderperformOutperformXOMAOutperform Votes44265.58% Underperform Votes23234.42% GX AcquisitionOutperform Votes2100.00% Underperform VotesNo Votes Do analysts prefer XOMA or GXGX? XOMA presently has a consensus price target of $69.50, suggesting a potential upside of 179.85%. Given XOMA's stronger consensus rating and higher probable upside, equities research analysts plainly believe XOMA is more favorable than GX Acquisition.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XOMA 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00GX Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more risk & volatility, XOMA or GXGX? XOMA has a beta of 0.89, suggesting that its stock price is 11% less volatile than the S&P 500. Comparatively, GX Acquisition has a beta of 0.17, suggesting that its stock price is 83% less volatile than the S&P 500. SummaryXOMA beats GX Acquisition on 12 of the 15 factors compared between the two stocks. Get GX Acquisition News Delivered to You Automatically Sign up to receive the latest news and ratings for GXGX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GXGX vs. The Competition Export to ExcelMetricGX AcquisitionPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$89.48M$6.47B$5.31B$8.28BDividend YieldN/A2.64%5.20%4.10%P/E RatioN/A8.9026.7319.58Price / SalesN/A257.08387.44119.65Price / CashN/A65.8538.2534.62Price / Book17.796.406.744.47Net Income-$49.26M$143.98M$3.23B$248.22M GX Acquisition Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GXGXGX AcquisitionN/A$2.49+18.6%N/A-39.7%$89.48MN/A0.00N/AGap DownXOMAXOMA4.067 of 5 stars$26.60-3.2%$69.50+161.3%-0.4%$328.85M$13.05M-7.6410Insider TradeHigh Trading VolumeABEOAbeona Therapeutics3.7866 of 5 stars$6.42+3.0%$18.50+188.2%+53.4%$313.30M$3.50M-2.39N/ATrending NewsAnalyst RevisionHigh Trading VolumePHATPhathom Pharmaceuticals3.8361 of 5 stars$4.38-0.2%$17.60+301.8%-59.1%$305.79M$81.86M-0.77110TRDAEntrada Therapeutics3.1101 of 5 stars$8.24+2.9%$25.67+211.5%-52.4%$304.00M$172.22M5.18110News CoverageAnalyst ForecastAnalyst RevisionIMMPImmutep1.2624 of 5 stars$2.01-1.5%$7.00+248.3%-36.9%$293.54M$5.14M0.002,021Analyst UpgradeHRTXHeron Therapeutics3.8199 of 5 stars$1.92flat$5.50+186.5%-46.1%$292.92M$148.52M-10.67300Analyst DowngradeNGNENeurogene2.3473 of 5 stars$18.55-5.0%$44.60+140.4%-44.3%$278.39M$925,000.00-4.2690Analyst ForecastGap UpTERNTerns Pharmaceuticals4.0883 of 5 stars$3.15flat$15.63+396.0%-50.4%$275.11MN/A-2.6740News CoveragePositive NewsGap DownNATRNature's Sunshine Products2.7467 of 5 stars$14.66-1.5%$18.33+25.1%-7.6%$269.03M$456.62M16.66850GOSSGossamer Bio3.7508 of 5 stars$1.18+8.3%$7.75+556.8%+81.7%$268.12M$114.70M-3.69180Analyst Revision Related Companies and Tools Related Companies XOMA Competitors ABEO Competitors PHAT Competitors TRDA Competitors IMMP Competitors HRTX Competitors NGNE Competitors TERN Competitors NATR Competitors GOSS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GXGX) was last updated on 5/23/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GX Acquisition Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share GX Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.